Yariswamy Manjunath1, Jonathan B Mitchem1, Kanve N Suvilesh2, Diego M Avella1, Eric T Kimchi1, Kevin F Staveley-O'Carroll1, Chelsea B Deroche3, Klaus Pantel4, Guangfu Li1, Jussuf T Kaifi5. 1. Department of Surgery, Health Management and Medical Informatics, University of Missouri, Columbia, Missouri; Surgical Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri. 2. Department of Surgery, Health Management and Medical Informatics, University of Missouri, Columbia, Missouri. 3. Biostatistics and Research Design Unit, Health Management and Medical Informatics, University of Missouri, Columbia, Missouri. 4. Institute for Tumor Biology, University of Hamburg, Hamburg, Germany. 5. Department of Surgery, Health Management and Medical Informatics, University of Missouri, Columbia, Missouri; Surgical Service, Harry S. Truman Memorial Veterans' Hospital, Columbia, Missouri. Electronic address: kaifij@health.missouri.edu.
Abstract
INTRODUCTION: Various subtypes of circulating cancer-associated cells in the blood are described. A unique circulating, large, and polymorphonuclear cell with a dual epithelial and myeloid phenotype has been suggested as a tumor-macrophage fusion cell (TMF). The goal of the study was to identify the impact of distinct TMFs on survival among patients with NSCLC. METHODS: In this prospective trial, 7.5 mL of whole blood sample was collected. After microfilter enrichment, immunofluorescent staining was performed, identifying TMFs as greater than or equal to 30 μm in size and dual epithelial (cytokeratin 8, 18, or 19-, or epithelial cell adhesion molecule-positive) and myeloid- or macrophage-positive (CD14- or CD45-positive) cells with at least one 4',6-diamidino-2-phenylindole+ nucleus. RESULTS: Circulating TMFs were identified in 88 of 115 patients (76.5%) with NSCLC (mean 3.052 [SEM ± 0.306]; median 2 [range 0-17]) but were rare in long-term smokers without cancer (6 of 87 [6.9%]; 0.081 [±0.034]; 0 [0-2]), and absent in 20 healthy controls. Comparing the presence of TMFs in patients with NSCLC versus smokers without cancer, specificity was 93.1% (95% confidence interval: 85.6-97.4%) and sensitivity 76.5% (95% confidence interval: 67.7%-83.9%). TMF counts correlated with American Joint Committee on Cancer tumor stages. More importantly, more than one TMF and giant TMFs sizes greater than or equal to 50 μm were associated with statistically significantly shorter overall and cancer-specific disease-free (p < 0.05) survival after curative resection for stage I to IIIA. Giant TMFs greater than or equal to 50 μm size were an independent survival predictor by multivariate analysis. CONCLUSIONS: Circulating, in particular, giant TMFs are associated with aggressive clinical behavior in surgically treated patients with NSCLC. The biological role of unique TMFs will need to be further investigated, as these may have a potential impact on immune responses toward cancer. Published by Elsevier Inc.
INTRODUCTION: Various subtypes of circulating cancer-associated cells in the blood are described. A unique circulating, large, and polymorphonuclear cell with a dual epithelial and myeloid phenotype has been suggested as a tumor-macrophage fusion cell (TMF). The goal of the study was to identify the impact of distinct TMFs on survival among patients with NSCLC. METHODS: In this prospective trial, 7.5 mL of whole blood sample was collected. After microfilter enrichment, immunofluorescent staining was performed, identifying TMFs as greater than or equal to 30 μm in size and dual epithelial (cytokeratin 8, 18, or 19-, or epithelial cell adhesion molecule-positive) and myeloid- or macrophage-positive (CD14- or CD45-positive) cells with at least one 4',6-diamidino-2-phenylindole+ nucleus. RESULTS: Circulating TMFs were identified in 88 of 115 patients (76.5%) with NSCLC (mean 3.052 [SEM ± 0.306]; median 2 [range 0-17]) but were rare in long-term smokers without cancer (6 of 87 [6.9%]; 0.081 [±0.034]; 0 [0-2]), and absent in 20 healthy controls. Comparing the presence of TMFs in patients with NSCLC versus smokers without cancer, specificity was 93.1% (95% confidence interval: 85.6-97.4%) and sensitivity 76.5% (95% confidence interval: 67.7%-83.9%). TMF counts correlated with American Joint Committee on Cancertumor stages. More importantly, more than one TMF and giant TMFs sizes greater than or equal to 50 μm were associated with statistically significantly shorter overall and cancer-specific disease-free (p < 0.05) survival after curative resection for stage I to IIIA. Giant TMFs greater than or equal to 50 μm size were an independent survival predictor by multivariate analysis. CONCLUSIONS: Circulating, in particular, giant TMFs are associated with aggressive clinical behavior in surgically treated patients with NSCLC. The biological role of unique TMFs will need to be further investigated, as these may have a potential impact on immune responses toward cancer. Published by Elsevier Inc.
Authors: Yariswamy Manjunath; Kanve Nagaraj Suvilesh; Jonathan B Mitchem; Diego M Avella Patino; Eric T Kimchi; Kevin F Staveley-O'Carroll; Klaus Pantel; Huang Yi; Guangfu Li; Peter K Harris; Aadel A Chaudhuri; Jussuf T Kaifi Journal: JCO Precis Oncol Date: 2022-03
Authors: Lucija Ačkar; Swaantje Casjens; Antje Andreas; Irina Raiko; Thomas Brüning; Maria Geffken; Sven Peine; Jens Kollmeier; Georg Johnen; Kai Bartkowiak; Daniel Gilbert Weber; Klaus Pantel Journal: Mol Oncol Date: 2021-10-03 Impact factor: 7.449
Authors: Thomas L Sutton; Ranish K Patel; Ashley N Anderson; Stephen G Bowden; Riley Whalen; Nicole R Giske; Melissa H Wong Journal: Cancers (Basel) Date: 2022-08-11 Impact factor: 6.575
Authors: Daniel J Gironda; Daniel L Adams; Jianzhong He; Ting Xu; Hui Gao; Yawei Qiao; Ritsuko Komaki; James M Reuben; Zhongxing Liao; Mariela Blum-Murphy; Wayne L Hofstetter; Cha-Mei Tang; Steven H Lin Journal: J Transl Med Date: 2020-11-04 Impact factor: 5.531